Cargando…

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy

OBJECTIVE: To report side effect frequency and severity in patients with major depressive disorder (MDD) receiving escitalopram and aripiprazole adjunctive therapy and to examine whether pretreatment anxious depression is associated with the number and presence of specific side effects. METHODS: 188...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espinola, Caroline W., Khoo, Yuelee, Parmar, Roohie, Demchenko, Ilya, Frey, Benicio N., Milev, Roumen V., Ravindran, Arun V., Parikh, Sagar V., Ho, Keith, Rotzinger, Susan, Lou, Wendy, Lam, Raymond W., Kennedy, Sidney H., Bhat, Venkat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120722/ https://www.ncbi.nlm.nih.gov/pubmed/35333448 http://dx.doi.org/10.1002/brb3.2555

Ejemplares similares

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
por: Islam, Farhana, et al.
Publicado: (2022)

Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression
por: Zhdanov, Andrey, et al.
Publicado: (2020)

The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report
por: Harkness, Kate L., et al.
Publicado: (2023)

Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report
por: Harris, Jacqueline K., et al.
Publicado: (2022)

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
por: Yrondi, Antoine, et al.
Publicado: (2019)

Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
por: Caspani, Giorgia, et al.
Publicado: (2021)

Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
por: Fiori, Laura M., et al.
Publicado: (2021)

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
por: Sajjadian, Mehri, et al.
Publicado: (2023)

“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19
por: Ceniti, Amanda K., et al.
Publicado: (2022)

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar, Fatemeh, et al.
Publicado: (2015)

Adjunctive treatment with aripiprazole for olanzapine-induced hyperprolactinemia
por: Bise, S., et al.
Publicado: (2022)

Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1
por: Nunez, John-Jose, et al.
Publicado: (2021)

A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study
por: Slyepchenko, Anastasiya, et al.
Publicado: (2023)

PS176. A functional resonance imaging investigation of escitalopram monotherapy in first episode depression
por: Ravindran, Arun V., et al.
Publicado: (2016)

Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants
por: Ju, Chelsey, et al.
Publicado: (2019)

Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

PS99. First episode depression and monotherapy with escitalopram: A 16-week, open-label, flexible-dose study
por: Ravindran, Arun V., et al.
Publicado: (2016)

Hypnic jerks possibly induced by escitalopram
por: Sathe, Harshal, et al.
Publicado: (2015)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
por: Oh, K.-S., et al.
Publicado: (2022)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants
por: Hassel, Stefanie, et al.
Publicado: (2019)

Exploring brain connectivity changes in major depressive disorder using functional‐structural data fusion: A CAN‐BIND‐1 study
por: Ayyash, Sondos, et al.
Publicado: (2021)

Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial
por: Cigognini, Marco Aurélio, et al.
Publicado: (2022)

The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study
por: Wallace, Caroline J. K., et al.
Publicado: (2021)

Stress Reduction through Audio Distraction in Anxious Pediatric Dental Patients: An Adjunctive Clinical Study
por: Singh, Divya, et al.
Publicado: (2014)

Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
por: Li, Xianbin, et al.
Publicado: (2013)

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
por: Nelson, J. Craig, et al.
Publicado: (2014)

Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019)

Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression
por: Farzan, Faranak, et al.
Publicado: (2017)

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor
por: Milev, Roumen
Publicado: (2015)

Escitalopram induced mania
por: Parker, Shubangi, et al.
Publicado: (2007)

Escitalopram in patients with psoriasis
por: Artemieva, M., et al.
Publicado: (2021)

Escitalopram Induced Angioedema
por: Conde, Samantha L, et al.
Publicado: (2022)

Adjunctive Treatment with Asenapine Augments the Escitalopram-Induced Effects on Monoaminergic Outflow and Glutamatergic Neurotransmission in the Medial Prefrontal Cortex of the Rat
por: Björkholm, Carl, et al.
Publicado: (2015)

Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
por: Marshe, Victoria S., et al.
Publicado: (2021)

Are there anxious genes?
por: Morris-Rosendahl, Deborah J.
Publicado: (2002)

An Anxious Succession
Publicado: (1893)

An Anxious Doctor
Publicado: (1891)

Cannot write session to /tmp/vufind_sessions/sess_ipptl345hfqrr32kjhc1k7rts6